Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F Fluciclovine PET for Cervical and Endometrial Cancer
NCT03423082Phase 4Terminated
- Start
- Dec 2018
- Primary completion
- Dec 2019
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial. Primary endpoint: Lesion Metabolic Avidity at 2 weeks. Started Dec 2018; status: terminated.
Beyond the preview
Go deeper on NCT03423082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03423082.